Invention Grant
US09213031B2 Use of Cbl as biomarker for identifying subject suitable for treatment with anti-c-Met antibody
有权
使用Cbl作为生物标志物,用于鉴定适合用抗c-Met抗体治疗的受试者
- Patent Title: Use of Cbl as biomarker for identifying subject suitable for treatment with anti-c-Met antibody
- Patent Title (中): 使用Cbl作为生物标志物,用于鉴定适合用抗c-Met抗体治疗的受试者
-
Application No.: US13949012Application Date: 2013-07-23
-
Publication No.: US09213031B2Publication Date: 2015-12-15
- Inventor: Ji Min Lee , Kyung Ah Kim , Bo Gyou Kim , Young Mi Oh , Saet Byoul Lee , Yun Ju Jeong
- Applicant: SAMSUNG ELECTRONICS CO., LTD.
- Applicant Address: KR Suwon-Si
- Assignee: SAMSUNG ELECTRONICS CO., LTD.
- Current Assignee: SAMSUNG ELECTRONICS CO., LTD.
- Current Assignee Address: KR Suwon-Si
- Agency: Leydig, Voit & Mayer, Ltd.
- Priority: KR10-2012-0080145 20120723; KR10-2012-0102395 20120914
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; G01N33/53 ; G01N33/574 ; C07K16/30 ; A61K39/395 ; C07K16/28 ; A61K39/00

Abstract:
A method of identifying a cell sample or a subject suitable for treatment with an anti-c-Met antibody or antigen binding fragment thereof that specifically binds to an epitope within a SEMA domain of a c-Met protein by determining a Cbl concentration, a Cbl mutation, and/or a mutation of a site of c-Met for interaction with Cbl in a cell sample from a subject, as well as related compositions and methods.
Public/Granted literature
- US20140105901A1 USE OF CBL AS BIOMARKER FOR IDENTIFYING SUBJECT SUITABLE FOR TREATMENT WITH ANTI-C-MET ANTIBODY Public/Granted day:2014-04-17
Information query